The company
Vaxinano develops needle-free nasal vaccines for human and animal health. Its proprietary Stellar-NP nanoparticle platform produces adjuvant-free vaccines that remain stable without strict cold-chain storage, which simplifies global distribution. Following a One Health approach, the company targets infectious diseases that pass between animals and humans, with lead programmes in leishmaniasis, toxoplasmosis and colibacillosis. In 2024, it granted Vetoquinol an exclusive licence for its canine leishmaniasis vaccine candidate.
